What is Cardio Diagnostics' operating income?

Cardio Diagnostics' total operating income in 2025 was -$6.48 million, based on the following breakdown: Total Gross Profit: $14.83 thousand Total Operating Expenses: $6.50 million

Cardio Diagnostics (CDIOW) Financials

$0.02 0.00 (0.00%)

As of 07/15/2026 12:21 PM Eastern

Compare

Annual Income Statements for Cardio Diagnostics

This table shows Cardio Diagnostics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-0.62	-4.66	-8.38	-8.38	-6.50
Consolidated Net Income / (Loss)	-0.62	-4.66	-8.38	-8.38	-6.50
Net Income / (Loss) Continuing Operations	-0.62	-4.66	-8.38	-8.38	-6.50
Total Pre-Tax Income	-0.62	-4.66	-8.38	-8.38	-6.50
Total Operating Income	-0.62	-4.55	-7.24	-8.37	-6.48
Total Gross Profit	0.00	0.00	0.02	0.03	0.01
Total Revenue	0.00	0.00	0.02	0.03	0.01
Operating Revenue	0.00	0.00	0.02	0.03	0.01
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	0.62	4.55	7.26	8.40	6.50
Selling, General & Admin Expense	0.47	4.40	6.94	6.92	5.03
Marketing Expense	0.10	0.09	0.16	1.23	0.77
Research & Development Expense	0.03	0.04	0.15	0.23	0.64
Depreciation Expense	0.02	0.02	0.02	0.02	0.07
Total Other Income / (Expense), net	0.00	-0.11	-1.13	-0.04	-0.03
Interest Expense	-	0.00	6.54	0.02	0.01
Interest & Investment Income	-	0.00	0.00	0.00	0.00
Other Income / (Expense), net	-	-0.11	5.41	-0.02	-0.01
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Basic Earnings per Share	-	($1.51)	($0.66)	($9.35)	($3.71)
Weighted Average Basic Shares Outstanding	-	3.09M	12.69M	896.42K	1.75M
Diluted Earnings per Share	-	($1.51)	($0.66)	($9.35)	($3.71)
Weighted Average Diluted Shares Outstanding	-	3.09M	12.69M	896.42K	1.75M
Weighted Average Basic & Diluted Shares Outstanding	-	9.61M	21.59M	52.15M	2.96M

This table shows Cardio Diagnostics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Consolidated Net Income / (Loss)	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Net Income / (Loss) Continuing Operations	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Total Pre-Tax Income	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Total Operating Income	-1.44	-1.54	-4.16	-1.28	-1.41	-1.52	-1.63	-1.68	-1.71	-1.46	-1.78
Total Gross Profit	0.01	0.01	0.02	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00
Total Revenue	0.01	0.01	0.02	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00
Operating Revenue	0.01	0.01	0.02	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	1.45	1.55	4.17	1.29	1.42	1.52	1.63	1.69	1.71	1.47	1.79
Selling, General & Admin Expense	1.38	1.49	4.12	1.29	1.42	0.09	1.28	1.69	1.71	0.08	1.46
Marketing Expense	0.03	0.04	0.03	-	-	-	0.19	-	-	-	0.20
Research & Development Expense	0.04	0.01	0.01	-	-	-	0.12	-	-	-	0.13
Depreciation Expense	0.00	0.00	0.00	-	-	-	0.05	-	-	-	0.01
Total Other Income / (Expense), net	-0.49	0.15	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.00	-0.01
Interest Expense	0.46	-0.35	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest & Investment Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income / (Expense), net	-0.03	-0.20	-0.01	-0.01	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	($0.16)	-	($5.93)	($1.71)	($1.73)	($1.69)	($0.97)	($0.97)	($0.98)	($0.84)	($0.63)
Weighted Average Basic Shares Outstanding	11.90M	12.69M	702.57K	753.59K	814.76K	896.42K	1.69M	1.74M	1.76M	1.75M	2.84M
Diluted Earnings per Share	($0.16)	-	($5.93)	($1.71)	($1.73)	($1.69)	($0.97)	($0.97)	($0.98)	($0.84)	($0.63)
Weighted Average Diluted Shares Outstanding	11.90M	12.69M	702.57K	753.59K	814.76K	896.42K	1.69M	1.74M	1.76M	1.75M	2.84M
Weighted Average Basic & Diluted Shares Outstanding	20.52M	21.59M	22.69M	23.94M	40.44M	52.15M	1.74M	1.76M	1.83M	2.96M	2.96M

This table details how cash moves in and out of Cardio Diagnostics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	0.28	3.60	-2.83	6.54	-2.72
Net Cash From Operating Activities	-0.59	-5.09	-5.67	-4.99	-5.73
Net Cash From Continuing Operating Activities	0.66	-5.09	-5.67	-4.99	-5.73
Net Income / (Loss) Continuing Operations	0.62	-4.66	-8.38	-8.38	-6.50
Consolidated Net Income / (Loss)	0.62	-4.66	-8.38	-8.38	-6.50
Depreciation Expense	-	0.00	0.00	0.11	0.16
Amortization Expense	0.02	0.02	0.11	0.16	0.24
Non-Cash Adjustments To Reconcile Net Income	0.06	0.11	2.38	2.59	0.11
Changes in Operating Assets and Liabilities, net	-0.04	-0.55	0.21	0.52	0.26
Net Cash From Investing Activities	-0.36	-0.37	-0.79	-0.40	-0.42
Net Cash From Continuing Investing Activities	-0.36	-0.37	-0.79	-0.40	-0.42
Purchase of Property, Plant & Equipment	-	0.00	-0.58	-0.21	-0.19
Acquisitions	-0.36	0.06	-0.20	-0.19	-0.23
Net Cash From Financing Activities	1.23	9.06	3.63	12	3.43
Net Cash From Continuing Financing Activities	1.23	9.06	3.63	12	3.43
Issuance of Common Equity	1.23	12	0.00	12	3.80
Other Financing Activities, net	0.00	-2.92	-0.87	-0.45	-0.37
Cash Interest Paid	0.00	0.01	0.03	0.02	0.01
Cash Income Taxes Paid	-	0.00	0.00	0.00	0.00

This table details how cash moves in and out of Cardio Diagnostics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-1.41	-2.35	0.28	-0.25	0.67	5.84	1.86	-1.72	-1.61	-1.24	1.97
Net Cash From Operating Activities	-1.04	-1.69	-1.23	-1.21	-1.16	-1.39	-1.40	-1.57	-1.39	-1.36	-1.56
Net Cash From Continuing Operating Activities	-1.04	-1.69	-1.23	-1.21	-1.16	-1.39	-1.40	-1.57	-1.39	-1.36	-1.56
Net Income / (Loss) Continuing Operations	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Consolidated Net Income / (Loss)	-1.93	-1.39	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Depreciation Expense	0.00	0.00	0.00	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04
Amortization Expense	0.04	0.06	0.02	0.05	0.05	0.05	0.09	0.05	0.05	0.05	0.05
Non-Cash Adjustments To Reconcile Net Income	0.55	-0.09	2.52	0.03	0.02	0.02	0.03	0.03	0.02	0.02	0.02
Changes in Operating Assets and Liabilities, net	0.30	-0.27	0.38	-0.03	0.15	0.02	0.08	-0.01	0.21	-0.01	0.11
Net Cash From Investing Activities	-0.09	-0.57	-0.07	-0.20	-0.08	-0.05	-0.05	-0.04	-0.26	-0.08	-0.06
Net Cash From Continuing Investing Activities	-0.09	-0.57	-0.07	-0.20	-0.08	-0.05	-0.05	-0.04	-0.26	-0.08	-0.06
Purchase of Property, Plant & Equipment	-0.01	-0.54	-0.02	-0.17	-0.02	-0.00	-0.01	-0.02	-0.16	-	-0.00
Acquisitions	-0.05	-0.03	-0.05	-0.03	-0.06	-0.05	-0.04	-0.02	-0.09	-0.08	-0.06
Net Cash From Financing Activities	-0.28	-0.09	1.58	1.16	1.91	7.29	3.31	-0.12	0.04	0.20	3.59
Net Cash From Continuing Financing Activities	-0.28	-0.09	1.58	1.16	1.91	7.29	3.31	-0.12	0.04	0.20	3.59
Issuance of Common Equity	-	-	1.72	1.30	2.00	7.37	3.42	-	0.12	0.26	3.69
Other Financing Activities, net	-0.28	-0.09	-0.14	-0.14	-0.09	-0.08	-0.12	-0.12	-0.08	-0.07	-0.10
Cash Interest Paid	0.01	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Income Taxes Paid	-	-	0.00	-	-	-	0.00	-	-	-	0.00

This table presents Cardio Diagnostics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1.10	6.25	4.46	11	7.77
Total Current Assets	0.80	5.89	2.77	8.79	5.92
Cash & Equivalents	0.51	4.12	1.28	7.83	5.11
Accounts Receivable	0.00	0.00	0.00	0.02	0.01
Prepaid Expenses	0.04	1.77	1.48	0.94	0.80
Plant, Property, & Equipment, net	0.00	0.00	0.57	0.67	0.70
Total Noncurrent Assets	0.30	0.36	1.12	1.15	1.15
Intangible Assets	0.30	0.36	0.54	0.71	0.87
Other Noncurrent Operating Assets	0.00	0.00	0.59	0.45	0.27
Total Liabilities & Shareholders' Equity	1.10	6.25	4.46	11	7.77
Total Liabilities	0.03	1.95	1.50	1.06	0.79
Total Current Liabilities	0.03	1.95	0.84	0.63	0.60
Accounts Payable	0.03	1.10	0.24	0.09	0.10
Other Current Liabilities	-	0.85	0.60	0.54	0.51
Total Noncurrent Liabilities	0.00	0.00	0.66	0.43	0.19
Other Noncurrent Operating Liabilities	0.00	0.00	0.66	0.43	0.19
Total Equity & Noncontrolling Interests	1.07	4.30	2.96	9.56	6.97
Total Preferred & Common Equity	1.07	4.30	2.96	9.56	6.97
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1.07	4.30	2.96	9.56	6.97
Common Stock	2.40	10	17	32	36
Retained Earnings	-1.33	-5.99	-14	-23	-29

This table presents Cardio Diagnostics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	5.96	4.33	4.00	4.48	12	10	8.79	9.56
Total Current Assets	4.52	2.59	2.14	2.63	11	8.70	6.93	7.74
Cash & Equivalents	3.63	1.56	1.31	1.98	9.69	7.97	6.36	7.08
Accounts Receivable	0.00	0.02	0.01	0.01	0.01	0.01	0.01	0.00
Prepaid Expenses	0.89	1.01	0.82	0.63	0.84	0.72	0.56	0.66
Plant, Property, & Equipment, net	0.04	0.59	0.72	0.71	0.64	0.62	0.74	0.66
Total Noncurrent Assets	1.40	1.15	1.14	1.15	1.11	1.07	1.12	1.16
Intangible Assets	0.51	0.58	0.61	0.66	0.70	0.71	0.80	0.93
Other Noncurrent Operating Assets	0.89	0.57	0.53	0.49	0.40	0.36	0.32	0.23
Total Liabilities & Shareholders' Equity	5.96	4.33	4.00	4.48	12	10	8.79	9.56
Total Liabilities	3.68	1.29	0.92	0.80	0.90	0.67	0.64	0.66
Total Current Liabilities	2.96	0.69	0.38	0.31	0.54	0.37	0.40	0.49
Accounts Payable	0.62	0.22	0.05	0.07	0.11	0.05	0.15	0.12
Other Current Liabilities	1.36	0.46	0.32	0.23	0.43	0.32	0.25	0.37
Total Noncurrent Liabilities	0.72	0.61	0.55	0.49	0.36	0.30	0.24	0.16
Other Noncurrent Operating Liabilities	0.72	0.61	0.55	-	0.36	0.30	0.24	0.16
Total Equity & Noncontrolling Interests	2.29	3.04	3.07	3.69	11	9.72	8.15	8.90
Total Preferred & Common Equity	2.29	3.04	3.07	3.69	11	9.72	8.15	8.90
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2.29	3.04	3.07	3.69	11	9.72	8.15	8.90
Common Stock	15	22	23	25	36	36	36	40
Retained Earnings	-13	-19	-20	-21	-24	-26	-28	-31

This table displays calculated financial ratios and metrics derived from Cardio Diagnostics' official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	9,514,743.00	20,516,940.00	40,439,810.00	1,826,051.00
DEI Adjusted Shares Outstanding	0.00	317,158.00	683,898.00	1,347,994.00	1,826,051.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-14.70	-12.25	-6.22	-3.56
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	5.44%	1,696.32%	104.45%	-57.51%
EBITDA Growth	0.00%	-668.47%	62.87%	-370.08%	24.76%
EBIT Growth	0.00%	-651.23%	60.60%	-356.56%	22.49%
NOPAT Growth	0.00%	-633.09%	-59.23%	-15.51%	22.49%
Net Income Growth	0.00%	-651.23%	-79.72%	-0.08%	22.49%
EPS Growth	0.00%	0.00%	56.29%	-0.08%	60.32%
Operating Cash Flow Growth	0.00%	-769.82%	-11.42%	11.97%	-14.69%
Free Cash Flow Firm Growth	0.00%	0.00%	-133.23%	9.88%	20.98%
Invested Capital Growth	0.00%	-66.83%	809.19%	3.33%	7.65%
Revenue Q/Q Growth	0.00%	0.00%	34.32%	-2.24%	-6.06%
EBITDA Q/Q Growth	0.00%	0.00%	28.81%	2.89%	0.75%
EBIT Q/Q Growth	0.00%	0.00%	25.85%	2.54%	0.56%
NOPAT Q/Q Growth	0.00%	0.00%	10.35%	0.31%	0.81%
Net Income Q/Q Growth	0.00%	0.00%	10.56%	-1.58%	0.82%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-1.58%	0.54%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	20.19%	5.55%	0.53%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	29.95%	-11.69%
Invested Capital Q/Q Growth	0.00%	0.00%	546.88%	-21.00%	3.69%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-67,086.35%	-488,945.79%	-10,106.18%	-23,236.19%	-41,146.97%
Operating Margin	-68,862.15%	-478,784.32%	-42,440.43%	-23,977.86%	-43,737.46%
EBIT Margin	-68,862.15%	-490,630.00%	-10,760.26%	-24,028.24%	-43,832.49%
Profit (Net Income) Margin	-68,862.15%	-490,630.00%	-49,087.81%	-24,028.24%	-43,832.49%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	456.20%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-78.21%	-861.07%	-545.49%	-343.98%	-252.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-41.91%	-797.27%	-423.02%	-288.50%	-222.36%
Return on Net Nonoperating Assets (RNNOA)	20.12%	687.47%	314.71%	210.02%	174.03%
Return on Equity (ROE)	-58.09%	-173.60%	-230.77%	-133.96%	-78.62%
Cash Return on Invested Capital (CROIC)	0.00%	-760.69%	-705.85%	-347.25%	-260.02%
Operating Return on Assets (OROA)	-56.30%	-126.80%	-34.28%	-111.20%	-70.70%
Return on Assets (ROA)	-56.30%	-126.80%	-156.40%	-111.20%	-70.70%
Return on Common Equity (ROCE)	-58.08%	-173.60%	-230.77%	-133.96%	-78.62%
Return on Equity Simple (ROE_SIMPLE)	-58.09%	-108.35%	-283.18%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.43	-3.18	-5.07	-5.86	-4.54
NOPAT Margin	-48,203.51%	-335,149.02%	-29,708.30%	-16,784.51%	-30,616.22%
Net Nonoperating Expense Percent (NNEP)	-36.30%	-63.80%	-122.46%	-55.48%	-30.29%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-171.38%	-61.27%	-65.09%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	52,226.75%	463,184.53%	40,648.38%	19,836.90%	33,899.29%
R&D to Revenue	3,492.56%	4,257.68%	850.76%	653.38%	4,325.21%
Operating Expenses to Revenue	68,962.15%	478,884.32%	42,540.43%	24,077.86%	43,837.46%
Earnings before Interest and Taxes (EBIT)	-0.62	-4.66	-1.84	-8.38	-6.50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.60	-4.64	-1.72	-8.11	-6.10
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	58.05	2.34	17.27	3.88	0.71
Price to Tangible Book Value (P/TBV)	80.57	2.56	21.10	4.19	0.81
Price to Revenue (P/Rev)	68,812.43	10,616.45	2,993.68	1,062.86	333.80
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	110.72	32.40	29.74	16.91	0.00
Enterprise Value to Revenue (EV/Rev)	68,243.32	6,282.22	2,918.47	838.52	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.48	-0.86	-0.74	-0.73	-0.78
Leverage Ratio	1.03	1.37	1.48	1.20	1.11
Compound Leverage Factor	1.03	1.37	6.73	1.20	1.11
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.99%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1,095.12	0.06	15.03	16.36	-3.47
Noncontrolling Interest Sharing Ratio	0.01%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	23.71	3.02	3.29	13.92	9.79
Quick Ratio	15.16	2.11	1.53	12.42	8.46
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2.81	-6.56	-5.91	-4.67
Operating Cash Flow to CapEx	0.00%	0.00%	-985.33%	-2,324.92%	-3,057.29%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-1.00	-317.16	-315.61
Operating Cash Flow to Interest Expense	0.00	0.00	-0.87	-267.87	-386.92
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-0.96	-279.39	-399.58
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	1.00	0.00	0.00	2.96	1.11
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.06	0.02
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	365.00	0.00	0.00	123.30	329.15
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	365.00	0.00	0.00	123.30	329.15
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.56	0.18	1.67	1.73	1.86
Invested Capital Turnover	0.00	0.00	0.02	0.02	0.01
Increase / (Decrease) in Invested Capital	0.00	-0.37	1.49	0.06	0.13
Enterprise Value (EV)	61	5.97	50	29	-0.16
Market Capitalization	62	10	51	37	4.95
Book Value per Share	$0.17	$0.45	$0.14	$0.24	$3.82
Tangible Book Value per Share	$0.12	$0.41	$0.12	$0.22	$3.34
Total Capital	1.07	4.30	2.96	9.56	6.97
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	-0.51	-4.12	-1.28	-7.83	-5.11
Capital Expenditures (CapEx)	0.00	0.00	0.58	0.21	0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.26	-0.18	0.64	0.33	0.21
Debt-free Net Working Capital (DFNWC)	0.77	3.94	1.92	8.16	5.32
Net Working Capital (NWC)	0.77	3.94	1.92	8.16	5.32
Net Nonoperating Expense (NNE)	0.19	1.48	3.31	2.53	1.96
Net Nonoperating Obligations (NNO)	-0.51	-4.12	-1.28	-7.83	-5.11
Total Depreciation and Amortization (D&A)	0.02	0.02	0.11	0.28	0.40
Debt-free, Cash-free Net Working Capital to Revenue	28,507.77%	-18,884.63%	3,756.31%	950.42%	1,384.38%
Debt-free Net Working Capital to Revenue	85,418.65%	414,538.63%	11,277.69%	23,385.17%	35,857.43%
Net Working Capital to Revenue	85,418.65%	414,538.63%	11,277.69%	23,385.17%	35,857.43%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.66)	($9.30)	($3.71)
Adjusted Weighted Average Basic Shares Outstanding	0.00	9.61M	12.69M	896.42K	1.75M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.66)	($9.30)	($3.71)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	9.61M	12.69M	896.42K	1.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	9.61M	21.59M	1.74M	2.96M
Normalized Net Operating Profit after Tax (NOPAT)	-0.43	-3.18	-5.07	-5.86	-4.54
Normalized NOPAT Margin	-48,203.51%	-335,149.02%	-29,708.30%	-16,784.51%	-30,616.22%
Pre Tax Income Margin	-68,862.15%	-490,630.00%	-49,087.81%	-24,028.24%	-43,832.49%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-0.28	-449.76	-439.04
NOPAT to Interest Expense	0.00	0.00	-0.78	-314.17	-306.66
EBIT Less CapEx to Interest Expense	0.00	0.00	-0.37	-461.28	-451.69
NOPAT Less CapEx to Interest Expense	0.00	0.00	-0.86	-325.69	-319.31
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Cardio Diagnostics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	11,776,213.00	20,516,940.00	21,591,119.00	22,685,589.00	23,942,447.00	40,439,810.00	52,145,416.00	1,738,710.00	1,763,129.00	1,826,051.00	2,959,469.00
DEI Adjusted Shares Outstanding	392,540.00	683,898.00	719,704.00	756,186.00	798,082.00	1,347,994.00	1,738,181.00	1,738,710.00	1,763,129.00	1,826,051.00	2,959,469.00
DEI Earnings Per Adjusted Shares Outstanding	-4.92	-2.03	-5.79	-1.70	-1.77	-1.13	-0.94	-0.97	-0.97	-0.80	-0.60
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	458.95%	0.00%	356.23%	-34.40%	-15.03%	-94.10%	-5.02%	-56.61%	-21.21%	185.11%
EBITDA Growth	-25.12%	29.40%	-203.68%	53.62%	7.31%	14.38%	63.49%	-32.08%	-22.17%	4.44%	-12.17%
EBIT Growth	-28.18%	26.92%	-204.51%	50.59%	4.25%	12.57%	60.73%	-30.68%	-21.38%	3.55%	-9.36%
NOPAT Growth	-25.49%	35.16%	-144.14%	49.77%	2.44%	1.66%	60.79%	-30.90%	-21.48%	3.51%	-9.46%
Net Income Growth	-67.91%	41.59%	-303.21%	67.98%	26.90%	-9.39%	60.73%	-30.68%	-21.38%	3.55%	-9.36%
EPS Growth	0.00%	0.00%	0.00%	67.98%	26.90%	0.00%	60.73%	43.27%	43.35%	50.30%	35.05%
Operating Cash Flow Growth	24.84%	45.98%	25.23%	6.38%	-10.79%	17.40%	-13.55%	-29.83%	-20.40%	2.19%	-11.58%
Free Cash Flow Firm Growth	0.00%	0.00%	-111.00%	-106.03%	-105.48%	56.53%	81.56%	69.89%	77.35%	-3.54%	-2.30%
Invested Capital Growth	-100.57%	809.19%	149.61%	244.53%	684.47%	3.33%	14.57%	-0.34%	-17.98%	7.65%	8.17%
Revenue Q/Q Growth	481.45%	-47.06%	199.96%	-50.59%	-16.39%	-31.43%	-79.17%	695.21%	-61.81%	24.52%	-24.61%
EBITDA Q/Q Growth	44.85%	-16.80%	-146.73%	70.81%	-10.21%	-7.89%	-5.21%	-5.58%	-1.94%	15.61%	-23.50%
EBIT Q/Q Growth	43.41%	-17.80%	-139.59%	69.07%	-9.67%	-7.56%	-7.62%	-2.94%	-1.86%	14.53%	-22.03%
NOPAT Q/Q Growth	43.43%	-6.77%	-169.65%	69.16%	-9.86%	-7.63%	-7.53%	-2.95%	-1.96%	14.51%	-21.98%
Net Income Q/Q Growth	51.97%	28.12%	-199.77%	69.07%	-9.67%	-7.56%	-7.62%	-2.94%	-1.86%	14.53%	-22.03%
EPS Q/Q Growth	58.97%	0.00%	0.00%	69.07%	-9.67%	-7.56%	-7.62%	0.00%	-1.03%	14.29%	25.00%
Operating Cash Flow Q/Q Growth	19.20%	-61.37%	26.85%	1.84%	4.38%	-20.30%	-0.56%	-12.24%	11.33%	2.27%	-14.71%
Free Cash Flow Firm Q/Q Growth	0.67%	-103.97%	-186.20%	47.21%	8.53%	68.54%	-21.39%	13.79%	31.21%	-43.82%	-19.94%
Invested Capital Q/Q Growth	69.30%	546.88%	-12.00%	19.71%	24.15%	-21.00%	-2.42%	4.13%	2.17%	3.69%	-1.95%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-14,307.07%	-31,563.33%	-25,962.12%	-15,335.15%	-20,213.51%	-31,802.66%	-160,611.06%	-21,325.16%	-56,915.87%	-38,573.59%	-63,190.52%
Operating Margin	-14,398.71%	-29,039.51%	-26,105.27%	-16,295.55%	-21,412.87%	-33,608.20%	-173,463.83%	-22,457.51%	-59,950.86%	-41,159.55%	-66,598.40%
EBIT Margin	-14,708.12%	-32,727.50%	-26,140.03%	-16,365.88%	-21,467.57%	-33,672.61%	-173,942.98%	-22,517.71%	-60,053.80%	-41,219.92%	-66,722.31%
Profit (Net Income) Margin	-19,266.02%	-26,156.86%	-26,140.03%	-16,365.88%	-21,467.57%	-33,672.61%	-173,942.98%	-22,517.71%	-60,053.80%	-41,219.92%	-66,722.31%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	130.99%	79.92%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-3.94%	-373.24%	0.00%	-1,642.80%	-589.30%	-482.14%	-1,528.49%	-174.12%	-332.27%	-237.76%	-439.43%
ROIC Less NNEP Spread (ROIC-NNEP)	72.63%	-361.78%	0.00%	-1,628.45%	-568.80%	-472.09%	-1,519.72%	-163.17%	-319.11%	-230.94%	-433.00%
Return on Net Nonoperating Assets (RNNOA)	-2.59%	269.15%	0.00%	1,480.51%	395.94%	343.66%	1,186.33%	118.26%	211.65%	180.74%	357.96%
Return on Equity (ROE)	-6.53%	-104.09%	-356.34%	-162.29%	-193.36%	-138.48%	-342.16%	-55.86%	-120.62%	-57.01%	-81.47%
Cash Return on Invested Capital (CROIC)	0.00%	-705.85%	-762.21%	-503.56%	-385.31%	-347.25%	-272.08%	-247.47%	-209.82%	-260.02%	-272.27%
Operating Return on Assets (OROA)	-5.21%	-104.28%	-133.93%	-119.13%	-146.70%	-155.84%	-416.84%	-61.04%	-142.84%	-66.49%	-101.21%
Return on Assets (ROA)	-6.82%	-83.34%	-133.93%	-119.13%	-146.70%	-155.84%	-416.84%	-61.04%	-142.84%	-66.49%	-101.21%
Return on Common Equity (ROCE)	-0.19%	-104.09%	-356.34%	-162.29%	-193.36%	-138.48%	-342.16%	-55.86%	-120.62%	-57.01%	-81.47%
Return on Equity Simple (ROE_SIMPLE)	-409.40%	0.00%	-378.94%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.01	-1.08	-2.91	-0.90	-0.99	-1.06	-1.14	-1.18	-1.20	-1.02	-1.25
NOPAT Margin	-10,079.10%	-20,327.66%	-18,273.69%	-11,406.89%	-14,989.01%	-23,525.74%	-121,424.68%	-15,720.26%	-41,965.60%	-28,811.69%	-46,618.88%
Net Nonoperating Expense Percent (NNEP)	-76.57%	-11.46%	-31.50%	-14.35%	-20.50%	-10.05%	-8.77%	-10.95%	-13.16%	-6.82%	-6.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-36.49%	-95.85%	-29.20%	-26.76%	-11.11%	-10.03%	-12.08%	-14.70%	-14.69%	-14.03%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	13,725.26%	28,092.77%	25,891.14%	16,395.55%	21,512.87%	2,022.96%	135,989.47%	22,557.51%	60,050.86%	2,331.98%	54,309.59%
R&D to Revenue	385.92%	141.09%	68.06%	0.00%	0.00%	0.00%	12,636.60%	0.00%	0.00%	0.00%	4,842.39%
Operating Expenses to Revenue	14,498.71%	29,139.51%	26,205.27%	16,395.55%	21,512.87%	33,708.20%	173,563.83%	22,557.51%	60,050.86%	41,259.55%	66,698.40%
Earnings before Interest and Taxes (EBIT)	-1.48	-1.74	-4.16	-1.29	-1.41	-1.52	-1.64	-1.68	-1.71	-1.47	-1.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.43	-1.68	-4.14	-1.21	-1.33	-1.43	-1.51	-1.59	-1.62	-1.37	-1.69
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.75	17.27	9.59	4.06	1.45	3.88	1.51	0.64	0.87	0.71	0.65
Price to Tangible Book Value (P/TBV)	2.25	21.10	11.87	5.06	1.76	4.19	1.61	0.69	0.96	0.81	0.72
Price to Revenue (P/Rev)	315.14	2,993.68	883.04	318.80	149.61	1,062.86	864.64	320.88	447.99	333.80	348.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	29.74	18.71	6.33	1.53	16.91	4.45	0.00	0.40	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	105.58	2,918.47	835.66	285.32	94.05	838.52	377.81	0.00	45.30	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.04	-0.74	-1.23	-0.91	-0.70	-0.73	-0.78	-0.72	-0.66	-0.78	-0.83
Leverage Ratio	1.06	1.48	1.99	1.80	1.75	1.20	1.15	1.12	1.12	1.11	1.08
Compound Leverage Factor	1.39	1.18	1.99	1.80	1.75	1.20	1.15	1.12	1.12	1.11	1.08
Debt to Total Capital	29.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	29.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	70.29%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.89	15.11	4.91	0.65	-3.02	18.49	9.17	2.51	2.48	-1.33	1.03
Noncontrolling Interest Sharing Ratio	97.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.53	3.29	3.78	5.69	8.51	13.92	19.49	23.55	17.39	9.79	15.76
Quick Ratio	1.23	1.53	2.31	3.50	6.47	12.42	17.94	21.59	15.98	8.46	14.41
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	65	-2.57	-7.35	-3.88	-3.55	-1.12	-1.36	-1.17	-0.80	-1.16	-1.39
Operating Cash Flow to CapEx	-8,296.39%	-313.88%	-6,169.88%	-720.92%	-4,978.74%	-38,270.89%	-24,193.90%	-8,405.35%	-855.73%	0.00%	-88,762.05%
Free Cash Flow to Firm to Interest Expense	141.63	0.00	-1,264.38	-667.43	-915.49	-357.27	-289.09	-249.29	-257.12	-504.66	-403.42
Operating Cash Flow to Interest Expense	-2.28	0.00	-211.97	-208.08	-298.37	-445.25	-298.47	-335.07	-445.47	-594.18	-454.26
Operating Cash Flow Less CapEx to Interest Expense	-2.31	0.00	-215.41	-236.94	-304.36	-446.41	-299.70	-339.05	-497.52	-594.18	-454.78
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	9.13	4.94	2.96	1.39	1.91	1.25	1.11	2.40
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.10	0.10	0.06	0.03	0.03	0.02	0.02	0.03
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	39.96	73.89	123.30	261.71	191.29	292.81	329.15	152.32
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	39.96	73.89	123.30	261.71	191.29	292.81	329.15	152.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.37	1.67	1.47	1.76	2.19	1.73	1.69	1.76	1.80	1.86	1.83
Invested Capital Turnover	0.00	0.02	-0.04	0.14	0.04	0.02	0.01	0.01	0.01	0.01	0.01
Increase / (Decrease) in Invested Capital	-66	1.49	4.44	2.98	2.56	0.06	0.21	-0.01	-0.39	0.13	0.14
Enterprise Value (EV)	1.34	50	28	11	3.36	29	7.52	-1.71	0.71	-0.16	-1.31
Market Capitalization	4.00	51	29	12	5.34	37	17	6.26	7.07	4.95	5.77
Book Value per Share	$0.19	$0.14	$0.15	$0.14	$0.15	$0.24	$0.22	$5.59	$4.62	$3.82	$3.01
Tangible Book Value per Share	$0.15	$0.12	$0.12	$0.11	$0.13	$0.22	$0.20	$5.18	$4.17	$3.34	$2.69
Total Capital	3.25	2.96	3.04	3.07	3.69	9.56	11	9.72	8.15	6.97	8.90
Total Debt	0.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2.66	-1.28	-1.56	-1.31	-1.98	-7.83	-9.69	-7.97	-6.36	-5.11	-7.08
Capital Expenditures (CapEx)	0.01	0.54	0.02	0.17	0.02	0.00	0.01	0.02	0.16	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.10	0.64	0.34	0.45	0.34	0.33	0.31	0.37	0.17	0.21	0.18
Debt-free Net Working Capital (DFNWC)	2.53	1.92	1.90	1.76	2.32	8.16	9.99	8.33	6.53	5.32	7.25
Net Working Capital (NWC)	1.57	1.92	1.90	1.76	2.32	8.16	9.99	8.33	6.53	5.32	7.25
Net Nonoperating Expense (NNE)	0.92	0.31	1.25	0.39	0.43	0.46	0.49	0.51	0.52	0.44	0.54
Net Nonoperating Obligations (NNO)	-2.66	-1.28	-1.56	-1.31	-1.50	-7.83	-9.69	-7.97	-6.36	-5.11	-7.08
Total Depreciation and Amortization (D&A)	0.04	0.06	0.03	0.08	0.08	0.08	0.13	0.09	0.09	0.09	0.09
Debt-free, Cash-free Net Working Capital to Revenue	-8,620.81%	3,756.31%	1,031.93%	1,155.68%	941.22%	950.42%	1,538.33%	1,882.66%	1,101.29%	1,384.38%	1,063.39%
Debt-free Net Working Capital to Revenue	19,947.85%	11,277.69%	5,769.71%	4,503.12%	6,496.56%	23,385.17%	50,220.47%	42,721.85%	41,370.07%	35,857.43%	43,786.13%
Net Working Capital to Revenue	12,335.22%	11,277.69%	5,769.71%	4,503.12%	6,496.56%	23,385.17%	50,220.47%	42,721.85%	41,370.07%	35,857.43%	43,786.13%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($1.80)	($1.80)	($50.70)	($0.97)	($0.97)	($0.98)	($0.84)	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	20.52M	12.69M	756.19K	753.59K	814.76K	29.88K	1.69M	1.74M	1.76M	1.75M	2.84M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($1.80)	($1.80)	($50.70)	($0.97)	($0.97)	($0.98)	($0.84)	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	20.52M	12.69M	756.19K	753.59K	814.76K	29.88K	1.69M	1.74M	1.76M	1.75M	2.84M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($50.70)	$0.00	$0.00	$0.00	($0.84)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	20.52M	21.59M	756.19K	798.08K	1.35M	1.74M	1.74M	1.76M	1.83M	2.96M	2.96M
Normalized Net Operating Profit after Tax (NOPAT)	-1.01	-1.08	-2.91	-0.90	-0.99	-1.06	-1.14	-1.18	-1.20	-1.02	-1.25
Normalized NOPAT Margin	-10,079.10%	-20,327.66%	-18,273.69%	-11,406.89%	-14,989.01%	-23,525.74%	-121,424.68%	-15,720.26%	-41,965.60%	-28,811.69%	-46,618.88%
Pre Tax Income Margin	-19,266.02%	-26,156.86%	-26,140.03%	-16,365.88%	-21,467.57%	-33,672.61%	-173,942.98%	-22,517.71%	-60,053.80%	-41,219.92%	-66,722.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3.22	0.00	-715.76	-221.42	-364.16	-485.87	-348.55	-358.89	-548.13	-639.34	-519.96
NOPAT to Interest Expense	-2.21	0.00	-500.37	-154.33	-254.26	-339.46	-243.32	-250.55	-383.03	-446.88	-363.30
EBIT Less CapEx to Interest Expense	-3.25	0.00	-719.20	-250.28	-370.15	-487.03	-349.79	-362.88	-600.18	-639.34	-520.48
NOPAT Less CapEx to Interest Expense	-2.24	0.00	-503.80	-183.19	-260.25	-340.62	-244.55	-254.54	-435.09	-446.88	-363.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Cardio Diagnostics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cardio Diagnostics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Cardio Diagnostics' net income appears to be on an upward trend, with a most recent value of -$6.50 million in 2025, rising from -$620.45 thousand in 2021. The previous period was -$8.38 million in 2024.

Cardio Diagnostics' total operating income in 2025 was -$6.48 million, based on the following breakdown:

Total Gross Profit: $14.83 thousand
Total Operating Expenses: $6.50 million

Over the last 4 years, Cardio Diagnostics' total revenue changed from $901.00 in 2021 to $14.83 thousand in 2025, a change of 1,545.4%.

Cardio Diagnostics' total liabilities were at $793.06 thousand at the end of 2025, a 25.0% decrease from 2024, and a 2,240.4% increase since 2021.

In the past 4 years, Cardio Diagnostics' cash and equivalents has ranged from $512.77 thousand in 2021 to $7.83 million in 2024, and is currently $5.11 million as of their latest financial filing in 2025.

Over the last 4 years, Cardio Diagnostics' book value per share changed from 0.17 in 2021 to 3.82 in 2025, a change of 2,116.4%.

Related Companies

Financial statements for NASDAQ:CDIOW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIOW) Financials

Financials Breakdown Chart

Cardio Diagnostics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIOW) Financials

Annual Income Statements for Cardio Diagnostics

Quarterly Income Statements for Cardio Diagnostics

Annual Cash Flow Statements for Cardio Diagnostics

Quarterly Cash Flow Statements for Cardio Diagnostics

Annual Balance Sheets for Cardio Diagnostics

Quarterly Balance Sheets for Cardio Diagnostics

Annual Metrics And Ratios for Cardio Diagnostics

Quarterly Metrics And Ratios for Cardio Diagnostics

Financials Breakdown Chart

Cardio Diagnostics Financials - Frequently Asked Questions

When does Cardio Diagnostics' fiscal year end?

How has Cardio Diagnostics' net income changed over the last 4 years?

What is Cardio Diagnostics' operating income?

How has Cardio Diagnostics' revenue changed over the last 4 years?

How much debt does Cardio Diagnostics have?

How much cash does Cardio Diagnostics have?

How has Cardio Diagnostics' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools